An investigation for investors in Gilead Sciences, Inc. (NASDAQ:GILD) shares over potential securities laws violations by Gilead Sciences, Inc. was announced and NASDAQ:GILD stockholders should contact the Shareholders Foundation at email@example.com
San Diego, CA -- (SBWIRE) -- 05/21/2013 -- An investigation on behalf of investors of Gilead Sciences, Inc. (NASDAQ:GILD) shares over potential securities laws violations by Gilead Sciences and certain of its directors and officers in connection certain financial statements was announced.
If you purchased shares of Gilead Sciences, Inc. (NASDAQ:GILD), you have certain options and you should contact the Shareholders Foundation at mail(at)shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Gilead Sciences, Inc. (NASDAQ:GILD) concerning whether a series of statements by Gilead Sciences, regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On Apr. 29, 2013, Gilead Sciences, Inc. announced that the company has received Complete Response Letters from the U.S. Food and Drug Administration for its New Drug Applications for elvitegravir and cobicistat for use as part of HIV treatment regimens.
In its communications, FDA states that it cannot approve the applications in their current forms. Gilead Sciences, Inc. said that the letters state that during recent inspections, deficiencies in documentation and validation of certain quality testing procedures and methods were observed.
Shares of Gilead Sciences, Inc. closed on May 20, 2013, at $55.74 per share.
Those who purchased shares of Gilead Sciences, Inc. (NASDAQ:GILD) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego